Docoh
Loading...

GTHX G1 Therapeutics

News

Pro users get this 30m faster
22 Stocks Moving in Friday's Pre-Market Session
15 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
G1 Therapeutics Announces Retrospective Analysis Of Pooled Results From Three Studies Shows COSELA Reduced Use Of Supportive Care Interventions In Extensive Stage Small Cell Lung Cancer Patients Who Receive The Drug Prior To Chemotherapy
7 Oct 21
Biotech, General
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that
G1 Therapeutics Announces Permanent J-Code From Centers For Medicare And Medicaid Services
1 Oct 21
Health Care, General
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
10 Biggest Price Target Changes For Thursday
30 Sep 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Jefferies raised Perrigo Company plc (NYSE: PRGO) price target from $45 to $63. Perrigo shares jumped 13.3% to $49.27 in pre-market trading.
JP Morgan Downgrades G1 Therapeutics to Neutral, Lowers Price Target to $20
30 Sep 21
News, Downgrades, Price Target, Analyst Ratings
JP Morgan analyst Anupam Rama downgrades G1 Therapeutics (NASDAQ:GTHX) from Overweight to Neutral and lowers the price target from $24 to $20.
G1 Therapeutics Announces New Supplemental COSELA Sales Force; Co. Will Hire And Train A 15-Person Oncology Sales Force To Supplement The Boehringer Ingelheim Oncology Commercial Team
15 Sep 21
News
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team. The
Roth Capital Maintains Buy on G1 Therapeutics, Lowers Price Target to $56
1 Sep 21
News, Price Target, Analyst Ratings
Roth Capital analyst Tony Butler maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $57 to $56.
Return on Capital Employed Overview: G1 Therapeutics
20 Aug 21
Earnings
Pulled from Benzinga Pro data G1 Therapeutics (NASDAQ:GTHX) reported Q2 sales of $6.60 million. Earnings fell to a loss of $38.19 million, resulting in a 49.57% decrease from last quarter.
G1 Therapeutics Q2 EPS $(0.94) Beats $(0.97) Estimate, Sales $6.60M Beat $2.59M Estimate
4 Aug 21
Earnings, News
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(0.97) by 3.09 percent. This is a 13.25 percent decrease over losses of $(0.83) per share from
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
4 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)
Earnings Scheduled For August 4, 2021
4 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
1 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

Press releases

Pro users get this 30m faster
Thinking about buying stock in Limelight Networks, G1 Therapeutics, Allegheny Technologies, Marathon Digital, or Nextplay Technologies?
15 Oct 21
Small Cap, Opinion, Press Releases
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLNW, GTHX, ATI, MARA, and NXTP.
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Oct 21
Markets, Press Releases
RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
1 Oct 21
Health Care, Press Releases, General
RESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
15 Sep 21
Press Releases, General
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person oncology sales force to
G1 Therapeutics to Participate in Two Upcoming September Conferences
3 Sep 21
News, Press Releases
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Sep 21
Press Releases
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an
G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
4 Aug 21
Earnings, Press Releases
- Achieved $6.6 Million in Total Revenue, including $2.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Initiated Pivotal Phase 3 Trial in Metastatic Triple-Negative Breast Cancer (TNBC)
G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)
4 Aug 21
Press Releases
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare & Medicaid Services (CMS) has
G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer
2 Aug 21
News, Management, Press Releases
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer
G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
28 Jul 21
News, Press Releases
RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial